The Group Room
Feature Interviews



Breast Cancer:
TOPIC GUEST DATE LISTEN
New treatment for Breast Cancer: Tykerb (lapatinib) Prof. Dr. Michael Untch
Head of the Clinic for Gynecology, Gynecology, Oncology and Obstetrics, Head of Breast Cancer Center, Helios Klinikum Berlin-Buch, Academic Hospital of the University Charite, Berlin, Germany
June 2006
42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, Georgia
Compliance and Adherence, Herceptin Victor Vogel, MD
Director, Magee/UPCI Breast Cancer Prevention Program, University of Pittsburgh School of Medicine, Professor of Medicine and Epidemiology, Magee-Womens Hospital, Pittsburgh, PA
Dec 2005
San Antonio Breast Cancer Symposium
Herceptin Edward Romond, MD
Associate Professor, Division of Hematology & Oncology, Department of Internal Medicine, University of Kentucky Markey Cancer Center, Lexington, KY
Dec 2005
San Antonio Breast Cancer Symposium
CellSearch,
Circulating tumor cells
Fred Smith, MD
Medical Oncologist, Sibley Memorial Hospital, Georgetown University, Washington DC
Dec 2005
San Antonio Breast Cancer Symposium
Herceptin Hope Rugo, MD
Clinical Professor of Medicine, Director of the Breast Oncology Clinical Trials Program, University of California, San Francisco
Dec 2005
San Antonio Breast Cancer Symposium
Breast Cancer Martine Piccart, MD, PhD
Associate Professor, Head of the Medicine Department, Jules Bordet Institute, Burssels, Belgium
Nov 2005
ECCO
Paris, France
Metastatic breast cancer - Clinical Trial on Lapatinib Kimberly Blackwell, MD
Assistant Professor of Medicine, Division of Hematology-Oncology, Duke University Medical Center, Durham, NC
December 2004
San Antonio Breast Cancer Symposium
Predicting response to chemotherapy & presence of metastatic disease in patients with breast cancer Massimo Cristofanilli, MD
Assistant Professor of Medicine, Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, TX
December 2004
San Antonio Breast Cancer Symposium
Prevention Clinical Trial for Breast Cancer for post-menopausal women Paul Goss, MD
Director of Breast Cancer Research, Massachusetts General Hospital; Professor of Medicine, Harvard Medical School, Boston, MA
December 2004
San Antonio Breast Cancer Symposium
General discussion on aromatase inhibitors for early stage breast cancer William Gradishar, MD, FACP
Director of Breast Medical Oncology, Associate Professor of Medicine, Co-Director, Lynne Sage Breast Cancer Program, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL
December 2004
San Antonio Breast Cancer Symposium
Aromatase inhibitors, hormonal management of breast cancer discussion, including Arimidex (Anastrazole) and ATAC trial (Arimidex & Tamoxifen: Alone or in combination) Generosa Grana, MD
Head, Division of Hematology & Medical Oncology, Cooper University Hospital; Associate Professor of Medicine, Robert Wood Johnson Medical School; Adjunct Assistant Professor, Coriell Institute for Medical Research, Camden, NJ
December 2004
San Antonio Breast Cancer Symposium
Aromatase inhibitors focusing on Aromasin for breast cancer Stephen Jones, MD
Medical Director, US Oncology Research; Chair, Breast Cancer Research Committee, US Oncology, Dallas, TX
December 2004
San Antonio Breast Cancer Symposium
Overview of 27th Annual San Antonio Breast Cancer Symposium Symposium C. Kent Osborne, MD
Director, Breast Center at Baylor College of Medicine; Professor of Medicine and Cellular & Structural Biology; Director, Baylor Cancer Center, Houston, TX
December 2004
San Antonio Breast Cancer Symposium
MA-17 Femara (Letrozole) study Victor Vogel, MD, MHS, FACP
Director, Magee/UPCI Breast Cancer Prevention Program, Professor of Medicine & Epidemiology, University of Pittsburgh School of Medicine, Magee Women's Hospital, Pittsburgh, PA
December 2004
San Antonio Breast Cancer Symposium
Overview of the 2nd Interamerican Breast Cancer Conference Eli Avisar, MD
Assistant Professor of Clinical Surgery, Co-Leader, Breast Site Disease Group, University of Miami School of Medicine, Miami, FL
July 2004
Cancun, Mexico
History and Description of Aromatase inhibitors Craig Henderson, MD
Adjunct Prof. of Medicine at the University of California San Francisco
June 2004
ASCO
New Orleans, LA
Aromatase inhibitors, focusing on Aromasin as treatment for breast cancer Per Lonning, MD, PhD
Head of the Breast Section Department of Oncology at Hockland University Hospital, Bergen, Norway
June 2004
ASCO
New Orleans, LA
Combination breast cancer treatment trial including herceptin with taxol and carboplatnin Nicholas Robert, MD
Fairfax Northern Virginia Hematology Oncology
June 2004
ASCO
New Orleans, LA
Scheduling of treatment of taxol for metastatic breast cancer Andrew Seidman, MD
Associate Attending for the Breast Cancer Mdeicine Service, Memorial Sloan-Kettering Cancer Center and an Associate Prof. of Medicine Weill Medical College of Cornell University
June 2004
ASCO
New Orleans, LA
Self-Breast Exam Anne Appleton, MD
Médecin-Chef de l'Unité de Sénologie, Clinique de Genolier
Stefan Gluck, MD, PhD
Professor, Division of Hematology/Oncology, University of Miami Sylvester Cancer Center
March 2004
EBCC
Hamburg, Germany
Cancer de sein Anne Appleton, MD
Médecin-Chef de l'Unité de Sénologie, Clinique de Genolier
March 2004
EBCC
Hamburg, Germany
Breast cancer program at the University of Miami, Florida Stefan Gluck, MD, PhD
Professor, Division of Hematology/Oncology, University of Miami Sylvester Cancer Center
March 2004
EBCC
Hamburg, Germany
Breast cancer treatment - Ellence (Epirubicin) Stefan Gluck, MD, PhD
Professor, Division of Hematology/Oncology, University of Miami Sylvester Cancer Center
March 2004
EBCC
Hamburg, Germany
Breast cancer Fritz Jänicke, MD, PhD
Chairman & Senior Professor for Obstetrics & Gynecology, University of Hamburg, Eppendorf
March 2004
EBCC
Hamburg, Germany
Significance of breast cancer treatment related fatigue Lonneke van de Poll-Franse, MD, PhD
Senior Researcher, Comprehensive Cancer Center South, Eindhoven, Netherlands
March 2004
EBCC
Hamburg, Germany
Adjuvant treatment for breast cancer Peter Barrett-Lee, MD
Oncologist, Velindre VHS Trust, Velindre Hospital, Cardiff, Wales
June 2, 2003
ASCO
Chicago
Male breast cancer Peter Barrett-Lee, MD
Oncologist, Velindre VHS Trust, Velindre Hospital, Cardiff, Wales
June 2, 2003
ASCO
Chicago
Cancer treatment-related fatigue in regard to treatment for breast cancer Julie Gralow, MD
Associate Professor, University of Washington School of Medicine Seattle, WA
June 2, 2003
ASCO
Chicago
Cancer treatment-related fatigue in regard to treatment for breast cancer Clifford Hudis, MD
Chief, Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY
June 2, 2003
ASCO
Chicago
Breast cancer advances in the UK Michael Richards, MD, PhD
National Cancer Director, NHS Executive, Department of Palliative Medicine, St. Thomas' Hospital, London, UK
June 2, 2003
ASCO
Chicago
Hormonal Therapy for Breast Cancer (2 tracks) Matthew Ellis, MD, PhD, FRCP
Director, Breast Cancer Program, Duke Comprehensive Cancer Center, Durham, NC
May 29, 2003
ASCO
Chicago
Combination therapy & metastatic breast cancer Denise Yardley, MD
Director of Breast Cancer Research, The Sarah Cannon Cancer Center, Nashville, TN
May 29, 2003
ASCO
Chicago
Die Optimierung von Hämoglobinwerten und darüber hinaus: Kraft zum Leben und bedeutsamen Überleben? Ursula Goldman-Posch
Mamazone, Frauen und Forschung gegen Brustkrebs e.V.
March 20, 2003
Vienna, Austria
 
 


Cancer Treatment-Related Fatigue and Anemia:
TOPIC GUEST DATE LISTEN
Cancer-related fatigue and anemia Roger Waltzman, MD
Assistant Prof. Dept. of Medicine, Section of Medical Oncology & Section of Palliative Medicine, St. Vincent's Hospital in New York City
June 2004
ASCO
New Orleans
Cancer-related fatigue and anemia in regards to treatment for breast cancer. Lonneke van de Poll-Franse, MD, PhD
Senior Researcher, Comprehensive Cancer Center South, Eindhoven, Netherlands
March 2004
EBCC
Hamburg, Germany
European Cancer Anemia Survey (ECAS) Peter Barrett-Lee, MD
Oncologist, Velindre VHS Trust, Velindre Hospital, Cardiff, Wales
June 2, 2003
ASCO
Chicago
Die Optimierung von Hämoglobinwerten und darüber hinaus: Kraft zum Leben und bedeutsamen Überleben? Jens-Uwe Blohmer, MD, PhD
Humboldt University, Berlin, Germany
March 20, 2003 Vienna, Austria
Cancer-related fatigue and anemia in regards to treatment Pere Gascon, MD, PhD
Director, Division of Medical Oncology Instituto de Enfermedades Hemato-Oncológicas Barcelona, Spain
March 20, 2003 Vienna, Austria
Die Optimierung von Hämoglobinwerten und darüber hinaus: Kraft zum Leben und bedeutsamen Überleben? Ursula Goldman-Posch
Mamazone, Frauen und Forschung gegen Brustkrebs e.V.
March 20, 2003 Vienna, Austria
Cancer-related fatigue and anemia Paul Harrison
Cancer patient
March 21, 2003 Vienna, Austria
Cancer-related fatigue, doctor/patient communication, quality of life Paul Harrison &
Timothy Littlewood, MD

John Radcliffe Hospital, Oxford, United Kingdom
March 21, 2003 Vienna, Austria
Die Optimierung von Hämoglobinwerten und darüber hinaus: Kraft zum Leben und bedeutsamen Überleben? Uwe Reinhardt, MD, PhD
Medizinische Klinik I, Hämatologie und Onkologie, Klinikum Bayreuth, Deutschland
March 20, 2003 Vienna, Austria
Cancer-related fatigue and anemia in regards to the treatment of gynecologic cancers. Maurice Schneider, MD, PhD
Professor in Medical Oncology at the Faculty of Medicine, Centre Antoine Lacassagne, Nice, France
March 20, 2003 Vienna, Austria
Die Optimierung von Hämoglobinwerten und darüber hinaus: Kraft zum Leben und bedeutsamen Überleben? Hans-Joachim Schmoll, MD, PhD
Direktor der Klinik und Poliklinik für Innere Medizin IV - Hämatologie/ Onkologie, Martin-Luther-Universität Halle-Wittenberg; Generalsekretär, Vital Options International, Deutschland
March 20, 2003 Vienna, Austria
Cancer-related fatigue and anemia in regards to treatment for gastrointestinal cancers. Dirk Schrijvers, MD
Medical Oncologist, Middelheim Hospital, Antwerp, Belgium, and Chair of the ESMO Education and Training Committee
March 21, 2003 Vienna, Austria
Au delà d'améliorer les niveaux d'hémoglobine: Le pouvoir de vie et de survie significative? Simon van Belle, MD, PhD
Department of Internal Medicine, University Hostpial Gent, Belgium
March 20, 2003 Vienna, Austria
 
 


Doctor-Patient Communication:
TOPIC GUEST DATE LISTEN
Doctor/Patient Communication and Information Exchange Paul Cornes, MD
Medical Oncologist, Clinical Oncology Research, Bristol Oncology Centre, United Kingdom
October 2004
ESMO
Vienna, Austria
Cancer-related fatigue, doctor/patient communication, quality of life. Paul Harrison &
Timothy Littlewood, MD

John Radcliffe Hospital, Oxford, United Kingdom
Senior Researcher, Comprehensive Cancer Center South, Eindhoven, Netherlands
March 21, 2003 Vienna, Austria
 
 


Gastrointestinal Cancers - Colorectal, Liver, Pancreatic:
TOPIC GUEST DATE LISTEN
Innovative Technology in the Treatment of Cancers Affecting the Liver Hans-Joachim Schmoll, MD, PhD
Director of the University Hospital for Internal Medicine IV, Hematology and Oncology, Martin Luther University Halle, Germany; Chairman of the German Association of Medical Oncology; President of the Cancer Society of the German State of Saxsen-Anhalt; General Secretary of Vital Options International, Germany
May 2005
ASCO
Orlando, FL
Colorectal Cancer ESMO 2004 Meeting Overview Roberto Labianca, MD, PhD
MOSES Working Group
June 2004
ASCO
New Orleans
Pancreatic cancer Roberto Labianca, MD, PhD
MOSES Working Group
June 2004
ASCO
New Orleans
Colorectal cancer Hans-Joachim Schmoll, MD, PhD
Director of the University Hospital for Internal Medicine IV, Hematology and Oncology, Martin Luther University Halle, Germany; Chairman of the German Association of Medical Oncology; President of the Cancer Society of the German State of Saxsen-Anhalt; General Secretary of Vital Options International, Germany
June 2004
ASCO
New Orleans
Colorectal cancer update Hans-Joachim Schmoll, MD, PhD
Director of the University Hospital for Internal Medicine IV, Hematology and Oncology, Martin Luther University Halle, Germany; Chairman of the German Association of Medical Oncology; President of the Cancer Society of the German State of Saxsen-Anhalt; General Secretary of Vital Options International, Germany
June 2003
ESEC
Edinburgh, Scotland
Colorectal cancer, MOSAIC study Aimery de Gramont, MD, PhD
Service de Médicine Interne-Oncologie, Hôpital Saint-Antoine Paris, France
June 2, 2003
ASCO
Chicago
Colorectal cancer Clare Topham, MD
Consultant, Clinical Oncology, NHS Trust, St. Luke's Cancer Center, Royal Surrey County Hospital & Mount Alvernia Hosptial Surrey, UK
June 2, 2003
ASCO
Chicago
Die Optimierung von Hämoglobinwerten und darüber hinaus: Kraft zum Leben und bedeutsamen Überleben? Hans-Joachim Schmoll, MD, PhD
Direktor der Klinik und Poliklinik für Innere Medizin IV - Hämatologie/ Onkologie, Martin-Luther-Universität Halle-Wittenberg; Generalsekretär, Vital Options International, Deutschland
March 20, 2003 Vienna, Austria
Cancer-related fatigue and anemia in regards to treatment for gastrointestinal cancers. Dirk Schrijvers, MD
Medical Oncologist, Middelheim Hospital, Antwerp, Belgium, and Chair of the ESMO Education and Training Committee
March 21, 2003 Vienna, Austria
 
 


Genetics:
TOPIC GUEST DATE LISTEN
Gynecologic cancer Agustin Garcia, MD
Director of Breast Cancer Research at the Women's Cancer Research Institute at Cedars-Sinai Medical Center, Los Angeles, CA
October 3, 2004
Counseling for genetic testing Talia Donnenberg
Board Certified Genetic Counselor, University of Miami School of Medicine, Sylvester Comprehensive Cancer Center
July 2004
2nd Interamerican Breast Cancer
Conference
Cancun, Mexico
 
 


Gynecologic Cancers:
TOPIC GUEST DATE LISTEN
Gynecologic cancer update Sergio Pecorelli, MD, PhD
Professor of Gynecologic Oncology, Chairman, Dept. of Obstetrics and Gynecology University of Brescia Brescia, Italy
June 2004
ASCO
New Orleans
Recurrent ovarian cancer Peter Rose, MD
Professor, Department of Obstetrics and Gynecology, MetroHealth Medical Center, Cleveland, OH
May 29, 2003
ASCO
Chicago
Cancer-related fatigue and anemia in regards to the treatment of gynecologic cancers. Maurice Schneider, MD, PhD
Professor in Medical Oncology at the Faculty of Medicine, Centre Antoine Lacassagne, Nice, France
March 20, 2003 Vienna, Austria
 
 


Leukemia/Lymphoma:
TOPIC GUEST DATE LISTEN
Lymphoma & multiple myeloma John Leonard, MD
Assistant Professor of Medicine, Assistant Attending Physician, Department of Hematology/Oncology, New York Weill Cornell Medical Center, New York, NY
June 2004
ASCO
New Orleans
Lymphoma John Leonard, MD
Assistant Professor of Medicine, Assistant Attending Physician, Department of Hematology/Oncology, New York Weill Cornell Medical Center, New York, NY
June 2, 2003
ASCO
Chicago
 
 


Lung Cancer:
TOPIC GUEST DATE LISTEN
Lung Cancer Christian Manegold, MD, PhD
Professor of Medicine, Interdisciplinatry Thoracic Oncology, Department of Surgery, Heidelberg University, Mannheim, Germany
Nov 2005
ECCO
Paris, France
Lung cancer Ronald Natale, MD
Senior Research Advisor, Salick Health Care, Inc., Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA
June 2004
ASCO
New Orleans
Lung cancer Nasser Hanna, MD
Assistant Professor, Department of Medicine, Division of Hematology/Oncology, University of Indiana, Indianapolis, IN
June 2, 2003
ASCO
Chicago
 
 


Multiple Myeloma:
TOPIC GUEST DATE LISTEN
Lymphoma & multiple myeloma John Leonard, MD
Assistant Professor of Medicine, Assistant Attending Physician, Department of Hematology/Oncology, New York Weill Cornell Medical Center, New York, NY
June 2004
ASCO
New Orleans
 
 


Prostate Cancer:
TOPIC GUEST DATE LISTEN
Targeted Therapy for Prostate Cancer Michael Carducci, MD
Associate Professor in Oncology and Urology, James Buchanan Brady Urological Institute, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD
May 2005
ASCO
Orlando, FL
 
 


Supportive Care:
TOPIC GUEST DATE LISTEN
Palliative Care Raphael Catane, MD, PhD
Chairman, Department of Oncology, Sheba Medical Center, Tel-Hashomer, Israel
Nathan Cherny, MD, PhD
Director, Cancer Pain & Palliative Medicine Service, Department of Oncology, Shaare Zedek Medical Center, Jerusalem, Israel
October 2004
ESMO
Vienna, Austria
Complementary & Alternative Medicine Patrick Mansky, MD
University Witten Herdecke Medical School, Memorial Sloan Kettering Cancer Center, NY; Metro Health Med. Ctr, CWRU, Cleveland, OH; Natl. Cancer Institute, NIH
June 2004 ASCO, New Orleans
 
 


Urinary Cancer:
TOPIC GUEST DATE LISTEN
Adjuvant chemotherapy for bladder cancer Anthony El-Khoureiry, MD
Clinical Instruction of Medicine, Division of Medical Oncology, USC Norris Comp. Cancer Center
June 2004
ASCO
New Orleans
 
 


American Society of Clinical Oncology (ASCO):
TOPIC GUEST DATE LISTEN
New treatment for Breast Cancer: Tykerb (lapatinib) Prof. Dr. Michael Untch
Head of the Clinic for Gynecology, Gynecology, Oncology and Obstetrics, Head of Breast Cancer Center, Helios Klinikum Berlin-Buch, Academic Hospital of the University Charite, Berlin, Germany
June 2006
42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, Georgia
ASCO Overview and Introduction, Situation in France Claude-Alain Planchon, MD
Département de Médicine Nucléaire, The American Hospital of Paris; Secrétaire Général, Vital Options International & Choix Vital, France
June 2004
ASCO
New Orleans
 
 


C-Change 2007 Annual Meeting:
TOPIC GUEST DATE LISTEN
Right to rehab for cancer patients; Quality of life/functioning after cancer; Cancer as a chronic disease
Paul Barnes
CEO, Navitas Cancer Rehabilitation Centers
October 2007
Washington, DC
Listen to this Feature Interview from the C-Change 2007 Annual Meeting
Patient care & pain management Pamela Bennett, RN, BSN
Executive Director, Healthcare Alliance Development, Purdue Pharma, LP; Past-President, American Society for Pain Management Nursing
October 2007
Washington, DC
Listen to this Feature Interview from the C-Change 2007 Annual Meeting
Public messaging: anti-smoking, nutrition, physical activity; Reaching underserved communities
Peggy Conlon
President & CEO, Advertising Council, Inc
October 2007
Washington, DC
Listen to this Feature Interview from the C-Change 2007 Annual Meeting
Patient care & oncology nursing: the role of the oncology nurse; Symptoms / symptom management
Georgia Decker, RN
President, Oncology Nursing Society
Paula Rieger, RN
Chief Executive Officer, ONS
October 2007
Washington, DC
Listen to this Feature Interview from the C-Change 2007 Annual Meeting
Caregiving & patient advocacy for rare cancers, esp. gall bladder; Psychosocial issues with rare cancer patients; Doctor/Advocacy group connections
Amy Dockser-Marcus
Staff Health Reporter, The Wall Street Journal; Recipient of Robert Wood Johnson Foundation Health Investigator Award for research on rare cancers
October 2007
Washington, DC
Listen to this Feature Interview from the C-Change 2007 Annual Meeting
Cervical cancer prevention Katherine Guccione
Manager, Public Policy and PR, Women in Government
October 2007
Washington, DC
Listen to this Feature Interview from the C-Change 2007 Annual Meeting
Cancer prevention research; Chemo prevention, cancer vaccines
Ronald Herberman, MD
Director, University of Pittsburgh Cancer Institute; Chair, C-Change Research Team
October 2007
Washington, DC
Listen to this Feature Interview from the C-Change 2007 Annual Meeting
Prevention and cancer control; Tobacco and disease prevention in Texas
Philip Huang
Medical Director of Chronic Disease Prevention, Texas Department of State Health Services; President-Elect of the National Association of Chronic Disease Directors
October 2007
Washington, DC
Listen to this Feature Interview from the C-Change 2007 Annual Meeting
Shortage of oncologists; Policy barriers to growing oncology workforce
Maureen Lichtveld, MD, MPH
Professor & Chair, Freeport McMoRan Chair of Environmental Policy; Associate Director, Louisiana Cancer Research Consortium
October 2007
Washington, DC
Listen to this Feature Interview from the C-Change 2007 Annual Meeting
Cancer prevention James Marks, MD, MPH
Senior Vice President & Director, Health Group, Robert Wood Johnson Foundation; Vice-Chairman, C-Change Board of Directors
October 2007
Washington, DC
Listen to this Feature Interview from the C-Change 2007 Annual Meeting
Compliance and side-effects Martin Murphy, Jr., PhD
Convener, CEO Roundtable on Cancer, Inc.
October 2007
Washington, DC
Listen to this Feature Interview from the C-Change 2007 Annual Meeting
Tobacco and smoking: countering the tobacco industry Matthew Myers, JD
President, Campaign for Tobacco-Free Kids
October 2007
Washington, DC
Listen to this Feature Interview from the C-Change 2007 Annual Meeting
Biomarker research development program Clet Niyikiza, MD
Vice President, Strategy Asset Management, GlaxoSmithKline
October 2007
Washington, DC
Listen to this Feature Interview from the C-Change 2007 Annual Meeting
What is an actuary?
- Chemo prevention
- Patient navigation
Bruce Pyenson
Principal & Consulting Actuary, Milliman, Inc.
October 2007
Washington, DC
Listen to this Feature Interview from the C-Change 2007 Annual Meeting
Detection and prevention; Access to medication
Gary Reedy
Worldwide Vice President, Biopharmaceutical Public Policy, Johnson & Johnson, C-Change Board Member
October 2007
Washington, DC
Listen to this Feature Interview from the C-Change 2007 Annual Meeting
Patient care and oncology social work; Side-effects; Navigating support options; POWER - Psychosocial Oncology Worldwide Education Resource; Social worker network
Kathryn Smolinski, MSW
Executive Director, Association of Oncology Social Work
Marcia DeSonier, MSW
President-Elect, AOSW
October 2007
Washington, DC
Listen to this Feature Interview from the C-Change 2007 Annual Meeting
Comprehensive cancer control; Distribution of physicians and centers / access to care; Physician collaboration
George Weiner, MD
Director, Holden Comprehensive Cancer Center
October 2007
Washington, DC
Listen to this Feature Interview from the C-Change 2007 Annual Meeting
Social barriers to men & proactive with health; Smoking and lung cancer, prostate cancer; "Get it checked" campaign; All men's health issues, not just cancer
Scott Williams
Director, Professional Relations & Public Policy, Men's Health Network
October 2007
Washington, DC
Listen to this Feature Interview from the C-Change 2007 Annual Meeting
Comprehensive cancer and health literacy; Children and young adults / prevention; Early detection; High school dropout rate and college enrollment levels
Governor Bob Wise
President, Alliance for Excellent Education
October 2007
Washington, DC
Listen to this Feature Interview from the C-Change 2007 Annual Meeting
Clinical Trials Robert Young, MD
Chancellor, Fox Chase Cancer Center
October 2007
Washington, DC
Listen to this Feature Interview from the C-Change 2007 Annual Meeting
 
 


European Cancer Conference (ECCO):
TOPIC GUEST DATE LISTEN
ECCO Harry Bartelink, MD, PhD
President of the Federation of European Cancer Societies (FECS) and the European Cancer Conference (ECCO); Professor and Chairman, Division of RadioTherapy, The Netherlands Cancer Institute, Anton van Leeuwenhoek Hospital, Amsterdam, Netherlands
Nov 2005
ECCO
Paris, France
ECCO Michael C.G. Stevens, MD, PhD
Royal Hospital for Children, Division of Child Health, Bristol, United Kingdom
Nov 2005
ECCO
Paris, France
Lung Cancer Christian Manegold, MD, PhD
Professor of Medicine, Interdisciplinatry Thoracic Oncology, Department of Surgery, Heidelberg University, Mannheim, Germany
Nov 2005
ECCO
Paris, France
ECCO Luigi Cataliotti, MD, PhD
President, European Society of Mastology; President, Surgery Department, University of Florence, Florence, Italy
Nov 2005
ECCO
Paris, France
Breast Cancer Martine Piccart, MD, PhD
Associate Professor, Head of the Medicine Department, Jules Bordet Institute, Burssels, Belgium
Nov 2005
ECCO
Paris, France
 
 


European Society of Medical Oncology (ESMO):
TOPIC GUEST DATE LISTEN
ESMO Gunta Purkalne, MD
Head, Radiation & Chemotherapy Centre, Stradins University Hospital, Riga, Latvia
May 2005
ASCO
Orlando, FL
ESMO Håkan Mellstedt, MD
President-Elect, European Society for Medical Oncology (ESMO); Professor of Oncologic Bioterapy Administrative Director, CancerCenter Karolinska; Chief Physician, Department of Oncology, Division of Oncologic Biotherapy, Karolinska Institutet, Stockholm, Sweden
May 2005
ASCO
Orlando, FL
ESMO Meeting, General Discussion Paul Cornes, MD
Medical Oncologist, Clinical Oncology Research, Bristol Oncology Centre, United Kingdom
October 2004
ESMO
Vienna, Austria
Global Core Curriculum in Medical Oncology Heine H. Hansen, MD, PhD
Professor, Finsen Centre, National University Hospital, Copenhagen, Denmark
October 2004
ESMO
Vienna, Austria
Overview of ESMO Meeting Heinz-Josef Lenz, MD
Associate Professor of Medicine and Preventive Medicine, Director, Colorectal Center and GI Oncology Program, USC/Norris Comprehensive Cancer Center, Los Angeles, CA
October 2004
ESMO
Vienna, Austria
Minimum Clinical Recommendations Rolf Stahel, MD, PhD
Department of Oncology, University Hospital, Zurich, Switzerland
October 2004
ESMO
Vienna, Austria
ESMO and the Cancer Patients Mario Dicato, MD, PhD
Departmental Head, Centre Hospitalier de Luxembourg
June 2004
ASCO
New Orleans
ESMO Patient Congress Paris Kosmidis, MD
President of the European Society for Medical Oncology (ESMO) Head of the Second Medical Oncology Dept., Hygeia Hospital, Athens, Greece
June 2004
ASCO
New Orleans
ESMO, colorectal cancer Roberto Labianca, MD, PhD
MOSES Working Group
June 2004
ASCO
New Orleans
ESMO Patient Congress Heinz Ludwig, MD, PhD
Head of the Department of Internal Medicine and Medical Oncology, Wilhelminen Hospital in Vienna, Chairman of the European Society for Medical Oncology (ESMO) Foundation and past president of ESMO
June 2004
ASCO
New Orleans
Organization of European Cancer Institutes (OECI) Mahasti Saghatchian, MD
Service Medical Oncology, Hospital George-Pompidou European, Paris
June 2004
ASCO
New Orleans
 
 


International Patient Issues:
TOPIC GUEST DATE LISTEN
ASCO Overview and Introduction, Situation in France Claude-Alain Planchon, MD
Département de Médicine Nucléaire, The American Hospital of Paris; Secrétaire Général, Vital Options International & Choix Vital, France
June 2004
ASCO
New Orleans
Donner la voix aux patients Roland Bugat, MD
Istitut Claudius Regaud, Centre Regional de Lutte Contre Le Cancer Midi-Pyrenees, Toulouse
Mario Dicato, MD, PhD
Departmental Head Centre Hospitalier de Luxembourg
June 2, 2003
ASCO
Chicago
The need for cancer talk in Spain Pere Gascon, MD, PhD
Director, Division of Medical Oncology Instituto de Enfermedades Hemato-Oncológicas Barcelona, Spain
June 2, 2003
ASCO
Chicago
The need for cancer talk in Italy Sergio Pecorelli, MD, PhD
Professor of Gynecologic Oncology, Chairman, Dept. of Obstetrics and Gynecology University of Brescia Brescia, Italy
June 2, 2003
ASCO
Chicago
 
 


San Antonio Breast Cancer Symposium:
TOPIC GUEST DATE LISTEN
Compliance and Adherence, Herceptin Victor Vogel, MD
Director, Magee/UPCI Breast Cancer Prevention Program, University of Pittsburgh School of Medicine, Professor of Medicine and Epidemiology, Magee-Womens Hospital, Pittsburgh, PA
Dec 2005
San Antonio Breast Cancer Symposium
Herceptin Edward Romond, MD
Associate Professor, Division of Hematology & Oncology, Department of Internal Medicine, University of Kentucky Markey Cancer Center, Lexington, KY
Dec 2005
San Antonio Breast Cancer Symposium
CellSearch,
Circulating tumor cells
Fred Smith, MD
Medical Oncologist, Sibley Memorial Hospital, Georgetown University, Washington DC
Dec 2005
San Antonio Breast Cancer Symposium
Herceptin Hope Rugo, MD
Clinical Professor of Medicine, Director of the Breast Oncology Clinical Trials Program, University of California, San Francisco
Dec 2005
San Antonio Breast Cancer Symposium
 
 


World Health Organization (WHO):
TOPIC GUEST DATE LISTEN
World Health Organization (WHO) Cancer Treaty Andreas Ulrich, MD, PhD
Medical Officer, Cancer Control Program, World Health Organization, Geneva, Switzerland
ESMO 2004
Vienna, Austria
 
 

 

 







HOME · ABOUT US · SUPPORT US · SEARCH · RESOURCES · THE GROUP ROOM · WRITE · TOP
Vital Options®, The Group Room®, TeleSupport®, Dance For Life®, The Cancer NewsMinute®, CancerTalk™, The Professor & The Survivor®, Cancer Options™, Advocacy in Action®, National Young Adult Cancer Awareness Week® and OncoTalk™ are trademarks of Vital Options International, Inc.

Copyright © 2012 Vital Options.   All Rights Reserved.
Web site by DE NOVO Medical Venture Marketing, a founding member of HSMN.


ds03